CAR T cell therapy for solid tumors: bright future or dark reality?
J Wagner, E Wickman, C DeRenzo, S Gottschalk - Molecular therapy, 2020 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
Cellular networks controlling T cell persistence in adoptive cell therapy
The antitumour activity of endogenous or adoptively transferred tumour-specific T cells is
highly dependent on their differentiation status. It is now apparent that less differentiated T …
highly dependent on their differentiation status. It is now apparent that less differentiated T …
Rapid manufacturing of non-activated potent CAR T cells
S Ghassemi, JS Durgin, S Nunez-Cruz… - Nature biomedical …, 2022 - nature.com
Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell
haematologic malignancies. The manufacturing of these T cells typically involves their …
haematologic malignancies. The manufacturing of these T cells typically involves their …
Metabolic challenges and interventions in CAR T cell therapy
Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …
Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15
Adoptive transfer of T lymphocytes expressing a CD19-specific chimeric antigen receptor
(CAR. CD19) induces complete tumor regression in patients with lymphoid malignancies …
(CAR. CD19) induces complete tumor regression in patients with lymphoid malignancies …
Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells
S Ghassemi, S Nunez-Cruz, RS O'Connor… - Cancer immunology …, 2018 - AACR
The success of chimeric antigen receptor (CAR)–mediated immunotherapy in acute
lymphoblastic leukemia (ALL) highlights the potential of T-cell therapies with directed …
lymphoblastic leukemia (ALL) highlights the potential of T-cell therapies with directed …
Paths to stemness: building the ultimate antitumour T cell
Stem cells are defined by the ability to self-renew and to generate differentiated progeny,
qualities that are maintained by evolutionarily conserved pathways that can lead to cancer …
qualities that are maintained by evolutionarily conserved pathways that can lead to cancer …
WNT signaling in cancer immunosurveillance
Deregulated WNT signaling has been shown to favor malignant transformation, tumor
progression, and resistance to conventional cancer therapy in a variety of preclinical and …
progression, and resistance to conventional cancer therapy in a variety of preclinical and …
[HTML][HTML] Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
DGM Tantalo, AJ Oliver, B von Scheidt… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most
promising approaches for the treatment of cancers. Large numbers of cancer reactive T …
promising approaches for the treatment of cancers. Large numbers of cancer reactive T …
Optimizing the manufacturing and antitumour response of CAR T therapy
Adoptive transfer of naturally occurring or genetically engineered T cells is an effective
treatment for certain haematological malignancies, such as non-Hodgkin lymphoma and …
treatment for certain haematological malignancies, such as non-Hodgkin lymphoma and …